Spec. Issue 2006 - Article Summary

Back to table of contents Spec. Issue 2006

Dendritic cell research projects

Pierre Aeby2, David Basketter1, Walter Diembeck3, Dietmar Eschrich4, Frank Gerberick5,
Hiroshi Itagaki6, Ian Kimber7, Béatrice Le Varlet 8, Irene Manou9, Marc Paye10, Françoise Rousset 11,
Joanna Rowland12 and Hitoshi Sakaguchi13

1Unilever Safety and Environmental Assurance Centre, Sharnbrook, UK; 2Cosmital (Wella), TOX, Marly, Switzerland;
3Beiersdorf, Hamburg, Germany; 4Phenion/Henkel, Frankfurt, Germany; 5The Procter & Gamble Company, Cincinnati, OH, USA;
6Shiseido Research Centre, Yokohama-Shi, Japan; 7Syngenta Central Toxicology Laboratory, Macclesfield, UK; 8LVMHRecherche,
Saint Jean de Braye, France; 9COLIPA, Brussels, Belgium; 10Colgate, R&D, Milmort, Belgium; 11L’Oreal, Advanced
Research, Aulnay sous Bois, France; 12GlaxoSmithKline, Consumer Healthcare, R&D, Weybridge, UK; 13Kao Corporation,
Tochigi, Japan

The Colipa Skin Tolerance Task Force (STTF) is playing an active role in promoting refined methods for in vivo sensitisation tests. Dendritic cells (DCs), whose central role during the induction phase of skin sensitisation is well documented, were perceived as promising
in vitro test systems. DC research projects supported by STTF evaluated the relevance of IL-1 âmRNA expression or changes in gene expression using gene microarrays for predicting potential sensitisers. Myeloid cell lines are being evaluated as surrogate DCs. Intracellular signal transduction pathways are being explored in order to understand the underlying biological mechanisms.

Nach oben